1
|
Chuang CY, Sung WW, Wang L, Lin WL, Yeh KT, Su MC, Hsin CH, Lee SY, Wu BC, Cheng YW, Lee H. Differential impact of IL-10 expression on survival and relapse between HPV16-positive and -negative oral squamous cell carcinomas. PLoS One 2012; 7:e47541. [PMID: 23118878 PMCID: PMC3485273 DOI: 10.1371/journal.pone.0047541] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2012] [Accepted: 09/13/2012] [Indexed: 11/30/2022] Open
Abstract
Human papillomavirus (HPV) is a risk factor in a subset of oropharyngeal cancer; however, the contribution of HPV in the malignancy of oral squamous cell carcinomas (OSCC) is not fully understood in Taiwanese. Herein, 61 patients with no risk factors and 117 patients with one or more risk factors were enrolled in this study. HPV16/18 infection rate in non-smokers, non-drinkers and non-betel quid chewers was higher than their counterparts. The development of HPV-infected cancer has been shown to be associated with interleukin-10 (IL-10) expression. To this end, IL-10 mRNA expression in OSCC tumors was evaluated by real-time RT-PCR. Data showed that HPV-positive patients had higher IL-10 mRNA levels than in HPV-negative patients. Kaplan-Meier and Cox-regression analysis indicated that the prognostic significance of IL-10 mRNA on overall survival and relapse free survival was only observed in HPV-positive OSCC, but not in HPV-negative OSCC. Mechanistically, the elevation of IL-10 by E6 was responsible for increased colony formation and migration capability in OSCC cells. Therefore, we suggest that IL-10 induced by E6 promotes cell growth and migration capability and consequent poor survival and relapse in HPV-positive OSCC.
Collapse
Affiliation(s)
- Chun-Yi Chuang
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, Republic of China
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan, Republic of China
- Department of Otolaryngology, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China
| | - Wen-Wei Sung
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, Republic of China
- Institute of Medical and Molecular Toxicology, Chung Shan Medical University, Taichung, Taiwan, Republic of China
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan, Republic of China
| | - Lee Wang
- School of Public Health, Chung Shan Medical University, Taichung, Taiwan, Republic of China
| | - Wea-Long Lin
- Department of Pathology, Chung Shan Medical University, Taichung, Taiwan, Republic of China
| | - Kun-Tu Yeh
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan, Republic of China
- Department of Pathology, Changhua Christian Hospital, Changhua, Taiwan, Republic of China
| | - Mao-Chang Su
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan, Republic of China
- Department of Otolaryngology, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China
| | - Chun-Han Hsin
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan, Republic of China
- Department of Otolaryngology, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China
| | - Shiann-Yann Lee
- Department of Otolaryngology, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China
| | - Buor-Chang Wu
- Department of Oral and Maxillofacial Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China
| | - Ya-Wen Cheng
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, Republic of China
- Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan, Republic of China
| | - Huei Lee
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, Republic of China
- Institute of Medical and Molecular Toxicology, Chung Shan Medical University, Taichung, Taiwan, Republic of China
- Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan, Republic of China
- * E-mail:
| |
Collapse
|